A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer

A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer

Abstract Aberrant EGFR signaling drives non‐small cell lung cancer (NSCLC) development, and despite the success of tyrosine kinase inhibitor (TKI) therapies in treating NSCLC, TKI resistance remains a major obstacle. Here, we report that the chemokine‐like transmembrane protein CMTM6 is physically a...

Full description

Saved in:
Bibliographic Details
Main Authors: Lu Xia, Jichuan Wang, Hui Xue, Haimeng Li, Qinghua Li, Sen Qin, Chunyu Yu, Yanhua Liu, Yu Gao, Lingyun Li, Sudun Guan, Enrun Zheng, Feiya Suo, Lin He, Yongsheng Wang, Wenling Han, Yongfeng Shang, Yong Geng, Luyang Sun
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Advanced Science
Subjects:
CMTM6
EGFR
EGFR‐TKIs resistance
NSCLC
nanobody
Online Access:https://doi.org/10.1002/advs.202410945
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/advs.202410945

Similar Items